Daré Bioscience (DARE) AI Stock Analysis

• Market Cap: $26.37M
• Dividend Yield: N/A
• Average Volume (3M): 17.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.32
• Revenue Growth: 88.13%
• EPS Growth: 92.45%
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -0.44
• Shares Outstanding: 8,850,386
• 10 Day Avg. Volume: 10,140
• 30 Day Avg. Volume: 17,342
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 8.06
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $12.00
• Price Target Upside: 302.68% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Daré Bioscience's stock score reflects significant financial challenges, including persistent unprofitability and high liabilities. Despite some technical indicators suggesting neutral momentum, the overall bearish trend weighs heavily. The recent earnings call showed some strategic progress, but financial issues and project delays remain key concerns. The lack of earnings and dividends further detracts from its valuation appeal.

Positive Factors

Financial Support

The recent grant from the Gates foundation injected ~$11M into the Ovaprene program, allowing DARE to expand enrollment sites.

Market Potential

Ovaprene is considered an exciting opportunity as it could be a blockbuster contraceptive device given the lack of convenient non-hormonal products on the market.

Regulatory Progress

Dare finalizes Phase 3 plan for sildenafil cream for treating FSAD with the FDA, aligning over the study design, endpoints, and patient population.

Negative Factors

Financial Risks

Risks include financial because the company has capital needs greater than the company's current cash balance, and it is likely going to need to raise additional capital.

Regulatory Challenges

Sildenafil cream is intriguing but still needs FDA alignment, and there is uncertainty around the regulatory pathway.

Daré Bioscience Business Overview & Revenue Model

Company Description

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.

How the Company Makes Money

Daré Bioscience makes money primarily through strategic partnerships, licensing agreements, and potential future revenues from product sales pending regulatory approval and commercialization. The company enters into collaborations with larger pharmaceutical companies for the development and commercialization of its product candidates, which can provide revenue in the form of milestone payments and royalties on sales. Additionally, Daré may receive funding and grants from government bodies or non-profit organizations focused on advancing women's health. Given that Daré is still in the clinical-stage, it relies heavily on investment capital and partnerships to finance its operations and support the advancement of its product pipeline.

Daré Bioscience Financial Statement Overview

Summary

Daré Bioscience faces significant financial challenges with consistent losses, negative equity, and heavy reliance on external financing. The company struggles with declining revenues and insufficient cash flow, indicating financial distress.

Income Statement

Daré Bioscience shows a challenging financial position with consistent net losses. The gross profit margin is relatively positive at 98.63%, but the net profit margin is negative due to high operating expenses, resulting in a loss of -1074.48%. Revenue growth is negative at -71.92% from the previous year, indicating declining sales performance. EBIT and EBITDA margins are also negative, reflecting the company's struggles to manage operational costs effectively.

Balance Sheet

The balance sheet reveals a concerning financial structure with negative stockholders' equity of -$5.05 million, indicating liabilities exceed assets. The debt-to-equity ratio cannot be calculated due to negative equity, implying high financial risk. The equity ratio is also negative, further highlighting financial instability. Return on equity is negative due to losses, suggesting poor profitability and potential financial distress.

Cash Flow

Cash flow analysis shows negative free cash flow growth, reflecting cash burn issues. Operating cash flow to net income ratio is negative, indicating insufficient cash generation to cover net losses. The company relies heavily on financing activities for cash flow, evident from significant financing cash inflow. Overall, cash flow management appears weak, with an inability to sustain operations without external financing.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
2.81M	10.00M	0.00	0.00	0.00
	Gross Profit
2.77M	9.95M	-26.41K	-43.23K	-11.14K
	EBIT
-30.84M	-31.39M	-39.07M	-27.40M	-14.34M
	EBITDA
-30.90M	-31.36M	-39.04M	-27.36M	-14.33M
	Net Income Common Stockholders
-30.16M	-30.95M	-38.33M	-27.40M	-14.26M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
10.48M	34.67M	51.67M	4.67M	4.78M
	Total Assets
21.28M	43.83M	55.81M	7.55M	7.44M
	Total Debt
1.40M	488.74K	270.55K	756.84K	800.45K
	Net Debt
-9.07M	-34.18M	-51.40M	-3.91M	-3.98M
	Total Liabilities
26.33M	32.71M	17.05M	8.70M	7.00M
	Stockholders Equity
-5.05M	11.11M	38.75M	-1.15M	440.83K
Cash Flow		Free Cash Flow
-39.49M	-18.15M	-28.78M	-25.25M	-13.32M
	Operating Cash Flow
-38.86M	-18.09M	-28.76M	-25.23M	-13.32M
	Investing Cash Flow
-629.43K	-63.07K	-14.52K	-17.63K	6.14M
	Financing Cash Flow
15.64M	1.34M	75.85M	25.13M	5.15M

Daré Bioscience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.98
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DARE, the sentiment is Negative. The current price of 2.98 is above the 20-day moving average (MA) of 2.93, above the 50-day MA of 2.96, and below the 200-day MA of 3.29, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.41 is Neutral, neither overbought nor oversold. The STOCH value of 21.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DARE.

Daré Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.36B	3.88	-42.93%	2.87%	17.85%	1.45%
VYNE	43 Neutral	$20.84M	―	-56.54%	―	18.16%	86.65%
DARE	41 Neutral	$26.37M	―	597.53%	―	88.13%	92.45%
PYPD	41 Neutral	$28.43M	―	-1038.73%	―	―	34.97%
CLNN	39 Underperform	$26.69M	―	-1738.36%	―	-47.71%	-244.00%
GBIO	38 Underperform	$29.21M	―	-91.02%	―	236.92%	-0.57%
NRSN	30 Underperform	$25.43M	―	-2880.11%	―	―	31.09%

Daré Bioscience Corporate Events

Daré Bioscience to Present at BIO CEO Conference

Daré Bioscience plans to present a corporate presentation at the BIO CEO & Investor Conference in New York on February 10, 2025, and use it in various meetings with market participants. The presentation will be available on their website, indicating a strategic move to engage with investors and stakeholders.